Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Genome-wide association studies in pharmacogenomics.

Daly AK.

Nat Rev Genet. 2010 Apr;11(4):241-6. doi: 10.1038/nrg2751. Review.

PMID:
20300088
2.

Methotrexate--how does it really work?

Chan ES, Cronstein BN.

Nat Rev Rheumatol. 2010 Mar;6(3):175-8. doi: 10.1038/nrrheum.2010.5.

PMID:
20197777
3.

Classical twin design in modern pharmacogenomics studies.

Rahmioğlu N, Ahmadi KR.

Pharmacogenomics. 2010 Feb;11(2):215-26. doi: 10.2217/pgs.09.171. Review.

PMID:
20136360
4.

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P.

PLoS Genet. 2009 Mar;5(3):e1000433. doi: 10.1371/journal.pgen.1000433. Epub 2009 Mar 20.

5.

Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate.

Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW.

Rheumatology (Oxford). 2009 Jun;48(6):613-7. doi: 10.1093/rheumatology/ken513. Epub 2009 Feb 4.

6.

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.

Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, Huizinga TW, Ten Cate R, Guchelaar HJ.

Arthritis Rheum. 2009 Jan 15;61(1):46-51. doi: 10.1002/art.24087.

7.

Pharmacogenetic relevance of MTHFR polymorphisms.

Toffoli G, De Mattia E.

Pharmacogenomics. 2008 Sep;9(9):1195-206. doi: 10.2217/14622416.9.9.1195. Review.

PMID:
18781847
8.

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ.

Blood. 2008 Aug 15;112(4):1022-7. doi: 10.1182/blood-2008-01-134247. Epub 2008 Jun 5.

9.

PLINK: a tool set for whole-genome association and population-based linkage analyses.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC.

Am J Hum Genet. 2007 Sep;81(3):559-75. Epub 2007 Jul 25.

10.

The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis.

Bartoli M, Tarò M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, Magnani A, Gasparini C, Martini A, Ravelli A.

Ann Rheum Dis. 2008 Mar;67(3):370-4. Epub 2007 Jul 27.

PMID:
17660217
11.

Juvenile idiopathic arthritis.

Ravelli A, Martini A.

Lancet. 2007 Mar 3;369(9563):767-78. Review.

PMID:
17336654
12.

Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.

Wessels JA, Kooloos WM, De Jonge R, De Vries-Bouwstra JK, Allaart CF, Linssen A, Collee G, De Sonnaville P, Lindemans J, Huizinga TW, Guchelaar HJ.

Arthritis Rheum. 2006 Sep;54(9):2830-9.

13.
15.

Haploview: analysis and visualization of LD and haplotype maps.

Barrett JC, Fry B, Maller J, Daly MJ.

Bioinformatics. 2005 Jan 15;21(2):263-5. Epub 2004 Aug 5.

16.

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.

Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A; Pediatric Rheumatology International Trials Organization.

Arthritis Rheum. 2004 Jul;50(7):2191-201.

17.

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J.

Nature. 2004 Feb 5;427(6974):537-41.

PMID:
14765194
18.

International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P; International League of Associations for Rheumatology.

J Rheumatol. 2004 Feb;31(2):390-2. No abstract available.

PMID:
14760812
19.

Use of methotrexate in juvenile idiopathic arthritis.

Ramanan AV, Whitworth P, Baildam EM.

Arch Dis Child. 2003 Mar;88(3):197-200. Review.

20.

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R.

Clin Pharmacol Ther. 2002 Dec;72(6):702-10.

PMID:
12496751
Items per page

Supplemental Content

Write to the Help Desk